CD8A and neoplasm: ICB and VEGF inhibitors: Antiangiogenic agents can promote normal vessel architecture, reduce hypoxia and improve antitumor immunity, by increasing CD8+ T-cell tumor infiltration, enhancing antigen presentation, or inducing TAM polarization to M1-subtype [224].